Form 4: NextCure Director David S. Kabakoff Granted 28,050 Stock Options

NextCure, Inc. Director David S. Kabakoff was granted 28,050 stock options with an exercise price of $0.47, vesting by June 2026.

Summary

• David S. Kabakoff, a Director of NextCure, Inc. (NXTC), was granted 28,050 stock options.
• The options have an exercise price of $0.47 per share.
• These options will vest in full on the earlier of June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders.
• The options are set to expire on June 19, 2035.
• Following this transaction, Mr. Kabakoff beneficially owns 28,050 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a standard compensation practice, aligning director interests with shareholders, which is generally viewed positively. However, it doesn't indicate immediate operational or financial performance changes.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The exercise price of $0.47 is relatively low, suggesting potential for future upside if the company's stock price increases.

Negatives

• No immediate negative financial implications from this specific Form 4 filing, as it reports an option grant rather than a sale or dilution event.

Risks

• The value of the granted stock options is contingent on the future performance of NextCure, Inc.'s stock price. If the stock price does not rise above the exercise price of $0.47, the options may expire worthless.
• The vesting schedule means the options are not immediately exercisable, and their value is subject to market fluctuations until vesting occurs.

Future Outlook

The granting of stock options to a director suggests a long-term incentive structure, aligning management's future performance with shareholder value creation, with vesting tied to future dates and the 2026 Annual Meeting of Stockholders.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation. In the biotechnology or pharmaceutical industry, attracting and retaining key talent, including directors, often involves equity-based compensation like stock options to incentivize long-term commitment and performance, given the long development cycles and high-risk nature of the business. Such grants are standard practice for aligning executive and director interests with company growth.

Comparison to Industry Standards

• The grant of stock options is a standard practice for compensating directors and executives across various industries, particularly in growth-oriented sectors like biotechnology.
• The specific number of options (28,050) and the exercise price ($0.47) would typically be evaluated against peer companies' compensation packages and the company's overall market capitalization and stage of development. Without specific peer data from comparable biotechnology companies at a similar stage, a direct quantitative comparison is not feasible from this document alone.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, potentially incentivizing long-term value creation and improved company performance.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Monitoring the vesting of the granted stock options on or before June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders.
• Observing any future exercises or sales of these options by David S. Kabakoff, which would be reported in subsequent Form 4 filings.

Key Dates

Keywords

NextCure Inc., NXTC, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership